Orexo AB
ORX SE0000736415
ICB 2010 : Health Care / Health CareSweden 751 05
SE-C Uppsala Box 303
Registration Number 556500-0600
Orexo is a Swedish pharmaceutical company that develops improved pharmaceuticals based on innovative formulation technologies that meet large medical needs. Through presence its in the US market, drugs and digital therapies are commercialized to treat opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with partners.
Founded 1994
Employees 126
http://www.orexo.com/
https://en.wikipedia.org/wiki/Orexo
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -52% | -50% | -22% | 18% | 5% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Transactions: 71 Insiders: 18
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Friedrich Von Bohlen |
1.84 EUR |
1,700 Bought |
3,128 EUR |
13/06/2025 | 11/06/2025 |
| Friedrich Von Bohlen |
1.89 EUR |
15,300 Bought |
28,917 EUR |
13/06/2025 | 11/06/2025 |
| Staffan Lindstrand |
15.28 SEK |
3,534 Bought |
54,000 SEK |
02/06/2025 | 02/06/2025 |
| Christine Elizabeth Rankin |
15.38 SEK |
3,314 Bought |
50,956 SEK |
26/05/2025 | 23/05/2025 |
| Nikolaj Arrild Sørensen |
14.87 SEK |
30,108 Bought |
447,706 SEK |
21/05/2025 | 19/05/2025 |
| Nikolaj Arrild Sørensen |
14.30 SEK |
2,460 Bought |
35,178 SEK |
17/04/2025 | 11/04/2025 |
| Fredrik Järrsten |
13.68 SEK |
2,000 Bought |
27,360 SEK |
21/05/2025 | 04/04/2025 |
| Nikolaj Arrild Sørensen |
13.58 SEK |
3,500 Bought |
47,530 SEK |
08/04/2025 | 04/04/2025 |
| Christine Elizabeth Rankin DIR |
21.28 SEK |
2,332 Bought |
49,625 SEK |
10/06/2024 | 07/06/2024 |
| James Noble CB |
20.80 SEK |
13,066 Bought |
271,773 SEK |
07/06/2024 | 05/06/2024 |